# Firefly Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/firefly-bio

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.fireflybiologics.com
- Total disclosed funding: $72M
- Latest round: Series A (Feb 15, 2024)
- Investors on record: 4

## About

Founded in 2022 and based in California, US, Firefly Bio, Inc. operates as a biotechnology platform that provides Degrader Antibody Conjugates for targeted therapy in medical treatments. The company was co-founded by Carolyn Bertozzi, John Flygare, and Bernhard Geierstanger. In June 2026, Johnson & Johnson, Inc. agreed to acquire Firefly Bio, Inc. from Versant Ventures, MPM BioImpact, and Decheng Capital for USD 1 billion in cash. 
The transaction is subject to customary closing condition and is expected to be completed later this year. As of February 2024, the company is led by its CEO Scott Hirsch. 

Firefly Bio, Inc.'s flagship product, Degrader Antibody Conjugates (DACs), leverages the precision of antibody conjugation and the power of selective protein degradation. The technology enables the selective degradation of disease-causing proteins within target tissues, minimizing off-target effects and maximizing therapeutic efficacy. The DAC candidates spanning various therapeutic areas including cancer and autoimmune disorders, with enhanced efficacy and reduced side effects.

The acquisition enables Johnson & Johnson to expand its oncology pipeline by adding Firefly Bio’s degrader antibody conjugate platform to develop targeted treatments for KRAS-driven cancers and other hard-to-treat tumors.

## Funding rounds

- Series A, Feb 15, 2024, $72M — Versant Ventures, MPM BioImpact, Decheng Capital, Eli Lilly & Company

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- Eli Lilly & Company — Series A